SYK Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of 15.18% compared to Stryker's net margin of 8.28%. Stryker's return on equity of 18.78% beat Globus Medical's return on equity of 2.27%.

Stryker has a consensus price target of $406.60, signalling upside risk potential of 11.52%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 14.04%. Given that Globus Medical has higher upside potential than Stryker, analysts believe Globus Medical is more attractive than Stryker.

Stryker has a beta of 0.938, which suggesting that the stock is 6.217% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Stryker has a quarterly dividend of $0.80 per share corresponding to a yield of 0.88%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 35.99% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.5B, which are larger than Globus Medical quarterly revenues of $625.7M. Stryker's net income of $834M is higher than Globus Medical's net income of $51.8M. Notably, Stryker's price-to-earnings ratio is 39.08x while Globus Medical's PE ratio is 123.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.39x versus 4.57x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 15.18% compared to Stryker's net margin of 27.73%. Stryker's return on equity of 18.78% beat Intuitive Surgical's return on equity of 15.9%.

Stryker has a consensus price target of $406.60, signalling upside risk potential of 11.52%. On the other hand Intuitive Surgical has an analysts' consensus of $556.42 which suggests that it could grow by 6.1%. Given that Stryker has higher upside potential than Intuitive Surgical, analysts believe Stryker is more attractive than Intuitive Surgical.

Stryker has a beta of 0.938, which suggesting that the stock is 6.217% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.383, suggesting its more volatile than the S&P 500 by 38.272%.

Stryker has a quarterly dividend of $0.80 per share corresponding to a yield of 0.88%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 35.99% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.5B, which are larger than Intuitive Surgical quarterly revenues of $2B. Stryker's net income of $834M is higher than Intuitive Surgical's net income of $565.1M. Notably, Stryker's price-to-earnings ratio is 39.08x while Intuitive Surgical's PE ratio is 84.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.39x versus 24.04x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of 15.18% compared to Stryker's net margin of -34.07%. Stryker's return on equity of 18.78% beat Treace Medical Concepts's return on equity of -49.68%.

Stryker has a consensus price target of $406.60, signalling upside risk potential of 11.52%. On the other hand Treace Medical Concepts has an analysts' consensus of $7.78 which suggests that it could grow by 11.94%. Given that Treace Medical Concepts has higher upside potential than Stryker, analysts believe Treace Medical Concepts is more attractive than Stryker.

Stryker has a beta of 0.938, which suggesting that the stock is 6.217% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Stryker has a quarterly dividend of $0.80 per share corresponding to a yield of 0.88%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 35.99% of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.5B, which are larger than Treace Medical Concepts quarterly revenues of $45.1M. Stryker's net income of $834M is higher than Treace Medical Concepts's net income of -$15.4M. Notably, Stryker's price-to-earnings ratio is 39.08x while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.39x versus 2.12x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of 15.18% compared to Stryker's net margin of 13.66%. Stryker's return on equity of 18.78% beat Zimmer Biomet Holdings's return on equity of 8.63%.

Stryker has a consensus price target of $406.60, signalling upside risk potential of 11.52%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $124.27 which suggests that it could grow by 16.01%. Given that Zimmer Biomet Holdings has higher upside potential than Stryker, analysts believe Zimmer Biomet Holdings is more attractive than Stryker.

Stryker has a beta of 0.938, which suggesting that the stock is 6.217% less volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 1.017, suggesting its more volatile than the S&P 500 by 1.712%.

Stryker has a quarterly dividend of $0.80 per share corresponding to a yield of 0.88%. Zimmer Biomet Holdings offers a yield of 0.9% to investors and pays a quarterly dividend of $0.24 per share. Stryker pays 35.99% of its earnings as a dividend. Zimmer Biomet Holdings pays out 19.62% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.5B, which are larger than Zimmer Biomet Holdings quarterly revenues of $1.8B. Stryker's net income of $834M is higher than Zimmer Biomet Holdings's net income of $249.1M. Notably, Stryker's price-to-earnings ratio is 39.08x while Zimmer Biomet Holdings's PE ratio is 20.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.39x versus 2.91x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.